Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

Article  PubMed  Google Scholar 

Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 2009;6:76–85.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7–33.

Article  PubMed  Google Scholar 

Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus Prednisone in Metastatic, castration-sensitive prostate Cancer. N Engl J Med. 2017;377:352–60.

Article  PubMed  CAS  Google Scholar 

Scher HI, Fizazi K, Saad F, Taplin M-E, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–97.

Article  PubMed  CAS  Google Scholar 

Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, et al. DNA-Repair defects and Olaparib in metastatic prostate Cancer. N Engl J Med. 2015;373:1697–708.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, et al. Update on systemic prostate Cancer therapies: management of metastatic castration-resistant prostate Cancer in the era of Precision Oncology. Eur Urol. 2019;75:88–99.

Article  PubMed  Google Scholar 

Sartor O, de Bono JS. Metastatic prostate Cancer. N Engl J Med. 2018;378:645–57.

Article  PubMed  CAS  Google Scholar 

Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fosså SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23.

Article  PubMed  CAS  Google Scholar 

Bouchelouche K, Turkbey B, Choyke PL. PSMA PET and Radionuclide Therapy in prostate Cancer. Semin Nucl Med. 2016;46:522–35.

Article  PubMed  PubMed Central  Google Scholar 

Kratochwil C, Giesel FL, Eder M, Afshar-Oromieh A, Benešová M, Mier W, et al. [177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:987–8.

Article  PubMed  Google Scholar 

Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate Cancer. N Engl J Med. 2021;385:1091–103.

Article  PubMed  PubMed Central  CAS  Google Scholar 

FDA Approves Pluvicto. Locametz for metastatic castration-resistant prostate Cancer. J Nucl Med. 2022;63:13 N.

Google Scholar 

Sadaghiani MS, Sheikhbahaei S, Werner RA, Pienta KJ, Pomper MG, Solnes LB, et al. A systematic review and Meta-analysis of the effectiveness and toxicities of Lutetium-177-labeled prostate-specific membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-resistant prostate Cancer. Eur Urol. 2021;80:82–94.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Haberkorn U, Giesel F, Morgenstern A, Kratochwil C. The future of Radioligand Therapy: α, β, or both? J Nucl Med. 2017;58:1017–8.

Article  PubMed  CAS  Google Scholar 

Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, et al. 225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-resistant prostate Cancer. J Nucl Med. 2016;57:1941–4.

Article  PubMed  CAS  Google Scholar 

Kratochwil C, Bruchertseifer F, Rathke H, Bronzel M, Weichert W, Haberkorn U, et al. Targeted α-Therapy of metastatic castration-resistant prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding. J Nucl Med. 2017;58:1624–31.

Article  PubMed  CAS  Google Scholar 

Sathekge MM, Lawal IO, Bal C, Bruchertseifer F, Ballal S, Cardaci G, et al. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH act): a multicentre, retrospective study. Lancet Oncol. 2024;25:175–83.

Article  PubMed  CAS  Google Scholar 

Morgan KA, Rudd SE, Noor A, Donnelly PS. Theranostic Nuclear Medicine with Gallium-68, Lutetium-177, Copper-64/67, Actinium-225, and Lead-212/203 radionuclides. Chem Rev. 2023;123:12004–35.

Article  PubMed  CAS  Google Scholar 

De Kruijff RM, Wolterbeek HT, Denkova AG. A critical review of alpha Radionuclide Therapy—How to Deal with recoiling daughters? Pharmaceuticals. 2015;8:321–36.

Article  PubMed  PubMed Central  Google Scholar 

Mease RC, Kang CM, Kumar V, Banerjee SR, Minn I, Brummet M, et al. An improved 211At-labeled agent for PSMA-targeted α-therapy. J Nucl Med. 2022;63:259–67.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zalutsky MR, Reardon DA, Pozzi OR, Vaidyanathan G, Bigner DD. Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies. Nucl Med Biol. 2007;34:779–85.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zalutsky MR, Pruszynski M. Astatine-211: production and availability. Curr Radiopharm. 2011;4:177–85.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lundh C, Lindencrona U, Schmitt A, Nilsson M, Forssell-Aronsson E. Biodistribution of Free 211At and 125I– in Nude mice bearing tumours derived from anaplastic thyroid carcinoma cell lines. Cancer Biother Radiopharm. 2006;21:591–600.

PubMed  CAS  Google Scholar 

Ukon N, Zhao S, Washiyama K, Oriuchi N, Tan C, Shimoyama S, et al. Human dosimetry of free 211At and meta-[211At]astatobenzylguanidine (211At-MABG) estimated using preclinical biodistribution from normal mice. EJNMMI Phys. 2020;7:58.

Article  PubMed  PubMed Central  Google Scholar 

Lindegren S, Albertsson P, Bäck T, Jensen H, Palm S, Aneheim E. Realizing clinical trials with Astatine-211: the Chemistry infrastructure. Cancer Biother Radiopharm. 2020;35:425–36.

PubMed  PubMed Central  Google Scholar 

Suzuki H, Kaizuka Y, Tatsuta M, Tanaka H, Washiya N, Shirakami Y, et al. Neopentyl Glycol as a Scaffold to provide Radiohalogenated Theranostic pairs of high in vivo Stability. J Med Chem. 2021;64:15846–57.

Article  PubMed  CAS  Google Scholar 

Cardinale J, Schäfer M, Benešová M, Bauder-Wüst U, Leotta K, Eder M, et al. Preclinical evaluation of 18F-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for prostate Cancer imaging. J Nucl Med. 2017;58:425–31.

Article  PubMed  CAS  Google Scholar 

Suzuki H, Kannaka K, Hirayama M, Yamashita T, Kaizuka Y, Kobayashi R, et al. In vivo stable 211At-labeled prostate-specific membrane antigen-targeted tracer using a neopentyl glycol structure. EJNMMI Radiopharm Chem. 2024;9:48.

Article  PubMed  PubMed Central  Google Scholar 

Wang X, Sun R, Wang J, Li J, Walker E, Shirke A, et al. A low molecular weight multifunctional theranostic molecule for the treatment of prostate cancer. Theranostics. 2022;12:2335–50.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Huang SS, Wang X, Zhang Y, Doke A, DiFilippo FP, Heston WD. Improving the biodistribution of PSMA-targeting tracers with a highly negatively charged linker. Prostate. 2014;74:702–13.

Article  PubMed